Sometimes It Takes Two NDAs For One Approval: Multaq Odyssey Shows FDA In Search Of Reassurance In Tricky Antiarrhythmic Field

FDA approval of Sanofi-Aventis’ Multaq (dronedarone) ultimately required six major clinical trials, four years, two NDAs – one with standard review designation, one with priority – and four separate claims proposed for the indication.